Evotec SE — Investor Presentation 2012

Jan 13, 2012

Best in Class Drug Discovery solutions -Evotec Company Overview

Evotec AG, General Company Overview, 30th Annual J.P. Morgan Healthcare Conference, San Francisco, January 2012

Forward-looking s statements

Information set forth in this presen forward-looking statements, which invo risks and uncertainties ncertainties. The forward forward-lo contained herein represent the judgemen the date of this report. Such forward-lo are neither promises nor guarantees, bu variety of risks and uncertainties, man ntation containsolve ^a number ofoking statements nt of Evotec as ofooking statements ut are subject to ^a ny of which are

beyond our control, and which could cause actual results to differ materially from those contemplated in these forward looking statements We ^e pressl disclaim an forward-lookingstatements. expressly any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Agenda

• Evotec at a glance

• Strategic background
• Discovery alliances & Development partnerships
• Financial strategy & Outlook

Leader in high qua ality drug discovery solutions

Evotec at a glance 1)

Agenda

• Evotec at a glance
• · Strategic background
• Discovery alliances & Development partnerships
• Financial strategy & Outlook

Outsourcing delive ers higher capital efficiency

Key factors underpinning Evotec's mission

5 1) Major players: Wuxi Pharma, Biofocus, AMRI, Syngene 2) WallStreet research 2008; evaluate Pharma; BioWorld e, PPD, Evotec, … ca. 100 fragmented smaller players

Managing the tran sition for long-term growth

Key strategy elements

~75% of revenues linked to milestones and royalties

Evotec Business model – P Performance based upside

Milestones allow for profitable gro owth and innovation investments

Agenda

• •Evotec at a glance
• •Strategic background
• • Discovery alliances & Developp p ment partnerships
• • Financial strategy & Out tlook

Drug discovery alliances & more

Our alliance model in drug discovery and product development

Highest productiv ity in discovery

"EVO Discover" – Best froom target to IND

Key strength y g

• Complete value chain, with all value creating steps in house (>100 lead series, >50 pre-clinical, 1( ⁰⁰ ead se es, ^{50 p e c} ca ,and clinical candidates)
• Proven target ID platform focusing on disease modifying mechanisms regenerating and protecting 2 , key tissues and cell types
• Industry leader in HTS and other platforms (e.g. FBDD, HCS, d th3compound management, chemoproteomics, phosphoproteomics) 2)
• High quality medicinal chemistry, supported by leading SGDD 3) and 4computational chemistry

• Comprehensive compound profiling 5

• 10 1) PDC … Preclinical Development Candidate

• 2) HTS … High throughput screening; FBBD … Fragment--based Drug Discovery (EVOlution); HCS … High Content Screening
• 3) SGDD … Structure based drug design

Strong portfolio of f top-class partners

Selected integrated drug d discovery alliances – targets provided by partners

P t a r n e r s	F o c u s a r e a	U i d f E t p s e o r v v o e c	D i i t e s c r p o n
	O l i n c o o g p a n y, , i f l i t n a m m a o n	+ + +	P f b d l i- l t t t t e r o r m a n c e a s e m a r g e o n g e r m u - - , l l i a a n c e
	H i d i t t u n n g o n s e a s e	+	f f L l l l l i i d h h i h t t t t t o n g e e r r m m a a a a n n c c e e o c u s e o n e e g - , i H i d i t t t a g a n s u n n g o n s e a s e
	V i a r o s u	+ +	L l l i f d l i l t t t t o n g e r m a a n c e o c s e o n m p e a r g e s u u - ,
	C N S 1 I l 2 m m n o o g u y	+ +	P f b d l l l i t e r o r m a n c e a s e o n g e r m a a n c e - - , , f d C N S / I l t t o c s e o n m m n o o g g a r e s u u y
	P i a n	+ +	f f P b d l l i d i e r o r m a n c e a s e a a n c e o c u s e o n p a n - ,
	V i a r o s u	+ +	P f b d l i- l t t t t e r o r m a n c e a s e m a r g e o n g e r m u - - , l l i a a n c e

Even higher upsid de if targets come from Evotec

Selected integrated drug d discovery alliances – targets provided by EVT

P t a r n e r s	F o c s a r e a u	i f U d E t p s e o r o e c v v	i i D t e s c r p o n
	M b l i t e a o c s ,	+ + + +	D i b b i d b l i d t t t a e e s o e s y a n m e a o c s y n r o m e ,
	i l i i i t n s u n s e n s z e r		R h f d i € f 7 t, e s e a r c n n g m p r o n u u , € i l l i 2 3 0 t t m m e s o n e s r o a e s y > ,
	B l l t e a c e f i t t r e g e n e r a o n a c o r	+ + + +	T 1 d 2 d i b i b l l t t t t y p e a n a e e s a r g e n g e a c e , f f R h d i € 5 t, m a s s e s e a r c u n n g m u p r o n , ,
			€ i i l l l i 2 5 0 t t t m m m e e s s o o n n e e s s r o a e s y > ,
	P i a n	+ + +	V R 1 A i t t, n a g o n s \$ f f P b d l l i 1 0 t, e r o r m a n c e a s e a a n c e m u p r o n - ,
			\$ i l l i 1 7 0 t t m m e s o n e s r o a e s y > ,
	R e s p o n s e d i i t p r e c o n	+ +	f f P b d l l i d e r o r m a n c e a s e a a n c e o c u s e o n - , f d l d i i t t e v e o p m e n o r e s p o n s e p r e c n g f b i k d i l d i i l o m a r e r s ; u n s c o s e n a n c a s

Deep clinical pipel line without risk

Portfolio of product develo opment partnerships

i i I d t n c a o n	P t a r n e r	S t t a s u	i U d p s e e f E t t o r o e c v	N t e x i l t m e s o n e	C i l o m m e r c a s
) 1 D i b t a e e s		P h I I I a s e	+ + +	F i l P h I I I d t n a a s e a a	M i l l i t t e s o n e s r o y a e s ; , i l k t t t p o e n a m a r e a p p r o x € 5 0 0 m
A l h i e m e r s z D i s e a s e		P h I I a s e	+ + + + + +	P h I I b i i i i t t a s e n a o n	M M i i l l l i t t t e e s s o o n n e e s s r o a e s y ; , i l k t t t p o e n a m a r e a p p r o x € 3– b 5 n
T i t t t t r e a m e n r e s s a n d i e p r e s s o n	O p e n	P h I I a s e	+ + +	N i t e p a r n e r n g w	O p e n
2 ) I i n s o m n a		P h I I a s e	+ +	P h I I b t t a s e s a r	M i l l i t t e s o n e s r o a e s y ,
P i a n		P h I a s e	+ +	P h I I t t a s e s a r	M i l l i t t e s o n e s r o a e s y ,
I f l i i t n a m m a o n n ) 3 i l h l h t a n m a e a		/ P h I I I a s e	+ + +	P h I I t t a s e s a r	M i l l i t t e s o n e s r o a e s y ,
4 ) ) O h t e r s	O p e n	P P l l i i i i l l r r e e -c c n n c c a a	+ + +	P i t a r n e r n g	O p e n

2) Chinese rights only; Safety and Phase IIb study planned d starting 2012

3) Animal Health (undisclosed)

4) EVT 501 (H3), P2X3, …

1) DiaPep277 is being developed by Andromeda Biotech L Ltd and has been partnered with TEVA Pharmaceuticals Industries Ltd

Novel treatment foor type 1 diabetes

Example 1: Product develo opment alliance with Andromeda/Teva (Phase III)

® D i P 2 A h i f l d i d 1 d i b 7 7 t t t t t t t a e p e r a p e u c r e a m e n o r n e w y a a g n o s e y p e a e e s –
T d i b l f h b d 's f i l d d i l i d 1 t t t t y p e a e e s r e s u s r o m e o y a u r e o p r o u c e n s u n a n • , l i l i f l i l i h b b i j i t t t t p r e s e n r e q r e s e o n g n s n e r a p s c a a n e o s n e c o n y u u y y u u u
f T d h i h b l l h d i i l i i t t t t t t t o a y e r e s n o e r a p y a e o s o w e e s r u c o n n o n s u n s e c r e n g • i b l l t t p a n c r e a c e a c e s
® D i P i d l d i d i i h i d l 2 7 7 t t t t t t t t a e p s a r g e e o r e a n e a g n o s e p a a e n s r e s a w y w u • , i l i i l l t n s n s e c r e n g c e s u

About DiaPep 277®

• • DiaPep 277®, is a unique peptide of 24 amino acids, d derived from human heat shock protein 60 (HSP 60)
• • The peptide acts by modulating the immune system, t that secrete insulin in response to elevated blood gluc thus preventing the destruction of pancreatic cells cose levels

DiaPep 277® is pro ogressing towards market entry

Example 1: Product develo opment alliance with Andromeda/Teva

D l b k d t e v e o p m e n a c g g r o u n	S t t a u s	E d k i l t t p e c e e m e s o n e s x y f E t o r o e c v
A l l d l l t, t e v e o p m e n r e g u a o r y • i b i l i i d h t t r e s p o n s e s a n c o s s a v e b f d t t e e n r a n s e r r e o ) 1 A d d / T n r o m e a e a v P h I d P h I I d i t a s e a n a s e s u e s • f f l l l l d d d d t t w e r e s u c c e s s u y c o n u c e T P h I I I d i h t t o a s e s e s a e o w u v • b d d f i i t t t e c o n c e o r r e g s r a o n u T h l d i d e v a a s a w o r w e • l i l i t e x c u s v e c e n s e o ® D i P 2 7 7 a e p p	® D i P 2 i 7 7 t a e p m m e p r m a r y • d i f t P h I I I i l 1 t s t e n p o n o a s e r a ( B l l f i ) t t t e a c e u n c o n ® D i P 2 d d d 7 7 t t a e p e m o n s r a e a • f f i i i i t t s g n c a n p r e s s e r v a o n o C C f f i i d d l l l l l k k t t -p e p e e v e s a m a r e r o r , i i l i i b t a s s e s s n g n s u n s e c r e o n y i l l t p a n c r e a c c e s s A d d i i l l i i l, f d t t o n a c n c c a s a e a n y • f f i l i i e c a c a n a s s o n g o n g y y d 2 P h I I I i h 0 0 t 5 n a s e w a p p r o x • i l d i i i d t t t t p a e n s w a s a r e a y n a e	N i l i i d t t t e x m e s o n e s r g g e r e • f i l l i f t 1 t s u p o n n a c o m p e o n o P h I I I d d d i i d d t t t t a s e s s u u y y a n c c o o n n n n u u e e l i i l d l ( i d t c n c a e e o p m e n m v ) 2 0 1 2 d d f f F F i i l l d d 2 2 P P h h I I I i i t t n n a a a o a s e n • / ( ) 2 0 1 4 2 0 1 5 e F i l j d f t t r s s a e s p r o e c e o r • / ( ) 2 0 1 5 2 0 1 6 e

Novel treatment off Alzheimer's disease

Example 2: Product develo opment alliance with Roche (Phase II)

About RG 1577– EVT 302

• • MAO-B is normally present in brain and is responsible e for break-down of certain neurotransmitters
• • Activity of MAO-B is linked to production roduction of reactive eactiveo damage oxygen species, molecules oleculesthat can cause neuronal euronal
• • Blocking the activity of MAO-B should reduce oxidativ ve stress which is expected to slow progression of AD

RG 1577/EVT302 –high unmet medical need

Example 2: Product develo opment alliance with Roche

D l b k d t e e o p m e n a c g g r o n v u	i i L t c e n s n g g a g g r e e e m e n	S d d k t t t a u s a n e x p e c e e y i l f E t t m e s o n e s o r v o e c
A l l d l l t, t e e o p m e n r e g a o r v u y • i b i l i i d h t t r e s p o n s e s a n c o s s a e v b f d R h t t e e n r a n s e r r e o o c e P h I d P h I I i l t a s e a n a s e r a s • h b d d i l l t t a e e e n c o n c e p a r a v u y i h d i f f h i l t t t t e r e n e r a p e c g o a s w u S f f i l i b l i h d t t a e p r o e s e s a s e y • f D l i l t e v e o p m e n p r o e c a n • i l l d l t t t t t p o e n a y a r g e s a n a o n e l i i t t t t a p p c a o n o r r e a m e n s	N f h E t t t t o r e r c o s s o o e c u v • \$ U f f 1 0 t t p r o n p a m e e n o m y • \$ M i l f 8 2 0 t e s o n e s o m • D b l d i i l i t t o u e g r o o y a e s •	L P h I I b i l i t a r g e a s e r a n • i f i 2 0 1 2 t t t p r e p a r a o n o r s a r n P h I I b l i d t a s e c o m p e o n a n • / P h I I I ( d ) 2 0 1 3 2 0 1 4 t t a s e s a r e n

Significant portfol io of high-value assets

Examples of other assets

H d & E b l l i i i i t t t t a r v a r v o e c e a c e n a	v e	i i N R 2 B l N M D A t t t s e e c e a n a g o n s s v – f d i i d i i t o r e p r e s s o n n c a o n s
S i b i d d h t t y s e m a c, u n a s e a n c o m p r e e n h f l b l l t t t s e a r c o r n o e e a c e a r g e s v I d i f h i l i l h i t e n p s o o g c a m e c a n s m s y y • h l b l l t t t t a c o n r o e a c e m a s s S l l i i t t t t t t e e c m o s r e e v a n a r g e s r r e s p e c v • d l i l l l l b i t t t t r e a m e n m o a s m a m o e c e s, y y u	i s v e f e o l i l o o g c a s …	P l i d l l i / N R B l i 2 t t, t t t o e n s e e c v e a n o r a y a c v e s e e c v e N M D A i ( E V T / ) 1 0 1 1 0 3 t t a n a g o n s s C l d l i l d f i d i d i t t t o m p e e m p e o s e n n g s e s u u • S l i d f f i l t o s a e y p r o e • D l i i t t e e o p m e n p a r n e r n g p r o c e s s o n g o n g v •
P 2 X 7 t r e c e p o r ( f d l t t p a r n e r e o r v e e r e n a r y u s e o n	) y	R d i i l f & h t t t t e s p o n s e p r e c o n p a o r m o e r a s s e s
i i i A T P d h l h h h t t -g a e o n c a n n e w c s o u g i l i i f l t t t m p o r a n r o e n n a m m a o r y p r o c e s	h l t t o p a y s e s	i i i f G l b l, l h l l l t t t t o a q u a n a v e a n a y s s o e c e u a r P h h t o s p o p r o e o m e

Upgrading initiativ ves for future discovery alliances

Examples to deliver innov vative technologies and even better services

C N h r e e p r o n u	i i S i F & B l H T t t r s e s n c a s s c r e e n n g
S i b i d d h i t t s e m a c, n a s e a n c o m p r e e n s e y u v h f l i h l t t s e a r c o r n o v e a r g e s n n e p r o o g y	S / i f b i h i l, f i l d l l l t c r e e n n g o r o c e m c a n c o n a a n o r c e a r u u i i h l i t t r e s p o n s e s u s n g p r o p r e a r y e c n o o g e s
I d i f h i l i l t e n y p y s o o g c a • h i d l t m e c a n s m s a n r e e v a n i i f t t t a r g e s r r e s p e c e o v d l i t t t t r e a m e n m o a y …	N i i d i t t t t e x g e n e r a o n s u p e r o r e e c o n • h l d i d t e c n o o g y a n n c r e a s e a s s a y i i i l i i h i h l i d t t t t t s e n s r e s n g n g e r q a a a v y u u y , l f l i i d f l i t t e s s a s e p o s e s a n a s e n e g a e s v v
C N u r e e u r o n	C d M t o m p o u n a n a g e m e n
S i i i b d d h t t y s e m a c, u n a s e a n c o m p r e e n s v e h f l i l t t s e a r c o r n o v e a r g e s n n e u r o o g y	i i i H h h d l d d t t t t g e c c o m p o u n o g s c s a n a a m a n a g e m e n i f P h d N G O s e r v c e o r a r m a a n s

Agenda

• Evotec at a glance
• Strategic background
• Discovery alliances & Development partnerships
• Financial strategy & Outlook

Positioning for sus

Strategic overview

Positive trend of aunderlying busine all key g metrics reflect strength of ess

Key metrics

in € m

Global reach for g approx. 600 scient lobal p j ro ects – tists

Evotec worldwide

Sales representation (Boston, Tokyo) Operations & sales representation

The right team to d industrialisationdeliver innovation, growth and

Management & sharehold der structure

Strong news flow to come

Outlook 2012

Key milestones for 2012

	B i l d l i i f i t t t u a e a s w o s g n c •
G d i r o w s c o v e r y 1 i l l a a n c e s	E d i i l t t p a n e s n g o n g e r x x • -

• • Build at least two signific cant new integrated discovery alliances
• •rm alliances
• • Show synergies from rec cent acquisitions

	G t e n e r a e
2	i l i l i t o p m a p p e n e
	p r o g r e s s

• • At l t i ifi t least one significants stt i raeg c d lf ea or cli i l ⁿ ca or pre-cli i l t linical asset
• • Deliver significant pre-cl inical/clinical milestones
• • Generate more innovatioon upsides within academic collaborations

3	f i b i l i t t p r o a y

• • Double-digit y-o-y reven ue growth
• Manage Improve profitability ove ^r 2011 without infringing innovation power 2011, innovation
• • Invest in high-tech upgra ade CAPEX program
• • Maintain strong strategic c cash position >€ 60 m

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax werner.lanthaler@evotec.com